Amy Kingman, MD
Cardiovascular Disease · Macon, GANPI 1992749659
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,920 of the $21,185 with a category attached, or 70.4%. Esperion Therapeutics, Inc. accounts for 73.6% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2021 at $10,229 and has fallen 92.0% since, to $819 in 2025. Among cardiovascular disease clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 212 payments — averaging $99.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$16K
- Abbott$2K
- Actelion Pharmaceuticals US, Inc.$500
- Amgen$462
- Johnson & Johnson$375
- Boston Scientific$339
- plus $2K from 16 others
What the payments were for
- Speaking & faculty fees$14,92070%
- Food & beverage$5,85628%
- Education$4092%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 22 | $15,582 |
| Abbott | 28 | $2,284 |
| Actelion Pharmaceuticals US, Inc. | 7 | $500 |
| Amgen | 20 | $462 |
| Johnson & Johnson | 31 | $375 |
| Boston Scientific | 17 | $339 |
| Novartis | 13 | $222 |
| Alnylam Pharmaceuticals Inc. | 4 | $183 |
| AstraZeneca | 12 | $177 |
| Merck | 8 | $158 |
| Tactile Systems Technology Inc | 2 | $153 |
| Pfizer | 9 | $151 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $133 |
| E.r. Squibb & Sons, L.L.C. | 9 | $130 |
| Medtronic(2 entities) | 7 | $101 |
| Philips North America LLC | 2 | $50 |
| Cvrx, Inc. | 3 | $46 |
| Novo Nordisk | 2 | $43 |
| Scpharmaceuticals Inc. | 2 | $36 |
| Regeneron Healthcare Solutions, Inc. | 2 | $26 |
| Boehringer Ingelheim | 2 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLIZET$15,045
- NEXLETOL$15,045
- AVEIR$526
- UPTRAVI$360
- OPSUMIT$360
- Repatha$247
- FLEXITOUCH$124
- ACTITOUCH$124
- ENTRE$124
- AMVUTTRA$124
- Allure Quadra RF CRT Pacemaker$111
- Confirm Rx$106
- QUADRA ASSURA$104
How this compares
$21,185 in reported general payments places this provider in the 90th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 719 | $611,708 |
| Repatha SureclickEvolocumab | 437 | $412,985 |
| EntrestoSacubitril/Valsartan | 405 | $398,375 |
| FarxigaDapagliflozin Propanediol | 423 | $307,958 |
| NexlizetBempedoic Acid/Ezetimibe | 159 | $156,546 |
| XareltoRivaroxaban | 160 | $139,793 |
| Praluent PenAlirocumab | 104 | $87,291 |
| VascepaIcosapent Ethyl | 80 | $42,221 |
| BrilintaTicagrelor | 31 | $32,810 |
| NexletolBempedoic Acid | 27 | $31,255 |
| Ezetimibe | 1,567 | $29,239 |
| Rosuvastatin Calcium | 1,774 | $21,334 |
| Repatha PushtronexEvolocumab | 17 | $18,423 |
| Metoprolol Succinate | 1,379 | $18,255 |
| Ranolazine ErRanolazine | 150 | $16,886 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $151 | $611,708719 claims |
| NovartisEntresto | $222 | $398,375405 claims |
| AstraZenecaFarxiga, Brilinta | $177 | $340,768454 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $15,582 | $187,801186 claims |
| Johnson & JohnsonXarelto | $375 | $139,793160 claims |
| MerckVerquvo | $158 | $7,92212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Macon
- Erskine JamesMacon$67K
- Julius ElmoreMacon$55K
- William KnopfMacon$43K
- Onajefe Nelson-TwakorMacon$23K
- Narendra SinghJohns Creek$1.6M
- Hunter ChampionColumbus$1.5M
- Nicolas ChronosEatonton$912K
- Jaime BurkleGainesville$628K
- Joseph MillerAtlanta$573K
- Kashyap ChoksiThomasville$263K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.